The discovery that hypercholesterolemia in patients with nephrotic syndrome is associated with elevated levels of PCSK9 enabled the successful use of evolocumab in this novel indication [128,129,130]. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.